Summit Therapeutics Share Discussion Threads

[waterloo01] 13/3/2018 16:29

Interesting stuff. Need to catch up but when they did the deal, I pointed out that prior to it they had been tweeting about gonorrhoea. Massive need here as the only remaining drug has started to develop resistance.

[hugus maximus] 13/3/2018 14:22

Perhaps the fact that news isn't being put about by the usual suspects (Seeking Alpha etc) means that unless on the RNS email list ... few yet know about todays news? (EDIT - and few are interested in anti-biotics in the USA)

Also a rather odd series of figures posted on Summit NASDAQ listing ... it closed last night around $13.4 which was certainly the case a few hours later ... then before business opened here this morning reportedly $13.7. Yet when the markets opened at lunch time here, it came in again around $13.4? So what looked like an immediate loss wasn't IMO the case. Most odd.

[solomon] 13/3/2018 13:40

For a couple of weeks USA east coast is only four hours behind us. Sarepta benefitting from Summit's news :-/

[hugus maximus] 13/3/2018 13:03

The share price has nicely moved up to the value that SMMT closed on the NASDAQ last night!

[phowdo] 13/3/2018 11:18

clap clap.

[football] 13/3/2018 11:15

Gonorrhoea only has one antibiotic left now that works against it I seem to remember from a TV report couple weeks ago this could be big news

[hugus maximus] 13/3/2018 11:06

RNS ... sounds good "the discovery of a series of antibiotic compounds that kill gonorrhoea bacteria via new mechanisms of action"

Summit's Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea

Oxford, UK, and Cambridge, MA, US, 13 March 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the discovery of a series of antibiotic compounds that kill gonorrhoea bacteria via new mechanisms of action. There is a pressing need for novel antibiotics targeting gonorrhoea due to increasing antibiotic resistance and a lack of new treatments. Gonorrhoea has been identified as one of three urgent threats by the US Centers for Disease Control and Prevention ('CDC'), and a high priority pathogen by the World Health Organisation ('WHO').

"Without truly novel mechanism antibacterial drugs we cannot address the issue of antimicrobial resistance. Nowhere is this need more obvious than in gonorrhoea, where increasing resistance and a lack of innovation means we are now nearing an era of untreatable disease," said Dr David Roblin, President of R&D of Summit. "Tackling this disease therefore fits squarely within Summit's strategic vision: the development of new mechanism therapies designed to treat specific diseases. This approach aims to demonstrate clear advantages over existing standards of care combined with a compelling value proposition for patients, payors and healthcare providers."

In early testing, the new series of antibiotic compounds has been shown to have high potency against strains of gonorrhoea with no development of resistance to date. The series of antibiotic compounds was identified using Summit's recently acquired technology platform. Summit intends to select a candidate from the gonorrhoea programme for entering into IND enabling studies in the second half of 2018. The Company believes the identified series of antibiotic compounds has the potential to produce a new front-line therapy for gonorrhoea.

Dr Roblin added, "We believe that these data demonstrate the power of our recently acquired technology platform to design and generate a pipeline of new mechanism antibiotics. This combines perfectly with our development capabilities and expertise already built in advancing ridinilazole, our late-stage precision antibiotic for C. difficile infection."

About Gonorrhoea
It is estimated by the WHO that there are approximately 106 million new cases of gonorrhoea globally per year. The US CDC reported in 2013 that 30% of new cases are resistant to at least one of the antibiotics currently used to treat gonorrhoea. Further the organism responsible for this infectious disease, Neisseria gonorrhoea, has consistently developed resistance to each class of antibiotics recommended for treatment. In 2006, the CDC recommended five treatment options. There is now only one treatment recommended by the CDC, a combination of two antibiotics. There are currently no other approved antibiotics that can be effectively deployed to target the disease.

About Summit's Technology Platform
The Summit infectious diseases technology platform combines transposon technology and bioinformatics to create and screen compounds against proprietary pathogen libraries. It can be used to identify new bacterial targets, elucidate mechanisms of action and help generate potential antibiotic candidates that are less susceptible to resistance development. The platform was obtained as part of the acquisition of Discuva Limited in December 2017.

[hugus maximus] 13/3/2018 09:03

Indeed football ... at close of NASDAQ it seemed way lower, then this morning nearly £2 at current exchange rate. Summit seems to be riding on Sarepta's wave.

Having once imagined that EZD eventually moves into the space currently occupied by Sarepta's dodgy Exon skipping drug, I'm beginning to fear any potential icebergs in their water (eg: EU approval) will actually hinder Summit's advance, as our success seems to now be inextricably linked to theirs ... interesting if slightly odd times!

[football] 12/3/2018 23:38

$13.74 increase0.54 (4.09%) ?????

[luminoso] 09/3/2018 21:10

Ah I see, thanks for the clarification, waterloo.

[filmster] 09/3/2018 18:53

I flew to Lisbon on the 1st March. That was quite a bumpy landing too.

[hugus maximus] 09/3/2018 18:15

Better than driving ... just incase you need a little comfort for the return journey :

[waterloo01] 09/3/2018 17:54

Not necessarily but the whole utrophin approach is to repair the muscle where it's been damaged by lack of dystrophin, so no not yet but they hope it will have the same effect.

o/T Survived flight to Lisbon through thunder storm, actually the pilots seem to weave around the worst of it. No one clapped once we landed, so guess it wasn't that bad just somewhat bouncy!

[hugus maximus] 09/3/2018 17:47

But can we compare dystrophin with utropin levels?

[waterloo01] 09/3/2018 17:45

I was just making the point that in the 24wk data, one of the criticisms was that Utrophin only increased by 7%, but the SRPT results showed that in their trial the uptake of dystrophin was even smaller, with only 2 of the 24 getting higher than 2% and about 50% significantly lower than that.

[luminoso] 09/3/2018 10:42

Hi waterloo, thanks for that post. When you say 'puts our results in focus', can you just clarify what bit of our results you are comparing to those SRPT dystrophin figures ? Apologies for being very unscientific here !
I agree that the collaboration with them may prevent some bang drumming on our part, in case we make them look bad.

[hugus maximus] 08/3/2018 18:35

The google input works - thanks Waterloo.

[waterloo01] 08/3/2018 17:19

This is an interest read and comparison (when we get the 48wk). I posted something last week about the amount of dystrophin needed in mice, suggesting greater than 19% needed and ideally 50%

Slide 16 shows that most boys hardly noticed any dystrophin and only 2 of the 24 show more than 2%. Put's our results into focus.

IF we didn't have the close relationship with SRPT I suspect we might be making more of the comparison.




Edit: not sure if the link works but if not google this and it should come up
Golodirsen Induces Exon Skipping
Leading to Sarcolemmal Dystrophin
Expression in Patients With Genetic
Mutations Amenable to Exon 53 Skipping

[chrisatrdg] 07/3/2018 21:08

NASDAQ up 5.85% to $13.40 being £1.93 UK value hopefully we will see further increases on AIM this Thursday.Exciting times.

[hugus maximus] 07/3/2018 19:56

In all our experience so far Summit have held an extremely tight ship ..,. this rise would be unusual if it were due to a news leak .... isn't this just sentiment for DMD research encouraged by SRPT's current success and folk are coming towards the field in general?